I'm watching Protalix, my carrot-media drug development startup investment. Nobel Prize winner Kornberg says (to Globes) that "I have high hopes for Protalix. It has created an important niche for itself, and is being managed properly."
Why has the FDA been giving it problems?
"There have not been any serious problems. The FDA even requested that development be accelerated when there was a shortage of the product. Only when the shortage ended did the FDA request additional information. Protalix is now on the verge of receiving FDA approval. "
I am losing 35% on Protalix but there is hope at the end of the tunnel. Kornberg has recently joined OphthaliX Inc., Can-Fite BioPharma Ltd.'s (TASE:CFBI) spin-off in the ophthalmic industry. OphthaliX develops ophthalmic products, and the Dry Eye Syndrome product is especially exciting because it is almost ready for market.
"I am sure this is just the tip of the iceberg, because these receptors have many implications," Kornberg says. "Can-Fite might create additional spin-offs in new areas in the future. I have not spoken with the company about this, but I know they are aware of the potential. In many cases, Dry Eye Syndrome is inflammatory. Today, it is believed that cancer also begins with inflammation. It may take some changes in molecules to realize the full potential of the drug in the future."
Fock you Kornberg. Now I'm attracted to the idea of getting MORE loans and invest inthese startups. Ne nos inducas in tentationem, sed libera nos a malo.
4 comments:
Kornberg said that? What does Carrotberg say?
Mehrenberg agrees: the carrot has great potential.
Sounds like something with great potential. Be forewarned though, the American FDA is a bloody night mare to deal with.
I know. First they asked to accelerate the development of Protalix, then delayed it by demanding more tests. It is such a powerful bureaucracy.
Post a Comment